Press Release

OBR to launch the 2014 OneStart £100K business competition for Life Sciences

Applications are invited from young enthusiastic Life Science Entrepreneurs for an opportunity to turn cutting edge research into a business plan. The winner receives a £100K no-string-attached start- up funding and free lab space to turn their innovative idea into a business.

Oxbridge Biotech Roundtable (OBR) has once again partnered with SR One to launch OneStart, a £100K biotech business competition. OneStart is the biggest competition of its kind and aims to launch the next generation of bio-entrepreneurs.

This year, there are two parallel competitions running in Europe and the Americas. The competition will be run in stages and covers four tracks: drug discovery, medical devices, diagnostics and health IT.  

Applications for the first round of submissions are now open and close on the 15^th of December 2013 at 11:59 PM Pacific Standard Time.  

Entrants must be under 35 years old as at 1^st January 2014 and can be individuals or a team.  The idea should be innovative and have an impact on health care. 35 Semi-finalist will be selected to attend an intensive business start-up workshop with the help of industry professionals. 10 finalists will be invited to pitch their business plan to a panel of experience biotech investors and the winner will be awarded the £100K prize investment.

Launch events for OneStart Europe are scheduled to take place in London, Cambridge, Oxford, Manchester, Glasgow and Liverpool.

Further information including launch dates, entry requirements, building a team and the application process is available at http://www.oxbridgebiotech.com/onestart/

Contact

onestart@oxbridgebiotech.com

Notes for editors

Oxbridge Biotech Roundtable is a campus led initiative established to bridge the gap between academia and industry. It seeks to strengthen communication channels between the two sectors through a mutualistic relationship of networking, education and consultancy.

SR One is the venture capital arm of GSK investing globally in promising emerging Life Science companies working on innovative science which will significantly impact health care.